Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AKCEA THERAPEUTICS, INC.AKCA · Entity 145982 | Director | July 13, 2017 | July 13, 2017 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director · Exec Chairman of the Board | January 26, 2021 | January 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AKCEA THERAPEUTICS, INC.
Report date July 13, 2017 · Filed July 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| No securities are beneficially owned.SEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2017-07-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
IONIS PHARMACEUTICALS INC
Report date January 26, 2021 · Filed January 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,021 |
Reported balance
After 2021-01-26 transaction · row 1
1 source rowRow 1 · 2021-01-26 · Sale · Disposed 28,333 · Balance 2,021 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy wife | 3,111 |
Reported balance
Holding disclosure · report date 2021-01-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,111 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 494,391 |
Reported balance
Holding disclosure · report date 2021-01-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 494,391 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,000 | $10.29 | $10,290.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 9 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. F4 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,000 | $35.10 | $35,100.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,170 F4 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. F4 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,000 | $10.29 | $10,290.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. F4 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 3,741 | $37.50 | $140,287.50 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,029 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 3,741 | $7.25 | $27,122.25 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 5 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 6,259 | $37.10 | $232,208.90 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,029 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.50, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 6,259 | $10.29 | $64,405.11 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $35.55 | $355,500.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,029 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F2 · price: The sale was a result of shares owned. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.10 to $36.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,000 | $10.29 | $102,900.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 21:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-16-000139 · edgar.xml · derivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 8,500 Underlying: Common Stock · 1,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 21:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-16-000139 · edgar.xml · derivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,259 Underlying: Common Stock · 10,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 21:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,000 | $36.61 | $36,610.00 |
DisclosureSEC source: 0000874015-16-000139 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,170 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 21:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,000 | $10.29 | $10,290.00 |
DisclosureSEC source: 0000874015-16-000139 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 21:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $36.61 | $366,100.00 |
DisclosureSEC source: 0000874015-16-000139 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,029 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 21:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,000 | $10.29 | $102,900.00 |
DisclosureSEC source: 0000874015-16-000139 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| September 27, 2016 Filed Sep 29, 2016 21:05 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-16-000138 · edgar.xml · derivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 9,500 Underlying: Common Stock · 2,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2016 Filed Sep 29, 2016 21:05 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmpoyee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-16-000138 · edgar.xml · derivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,259 Underlying: Common Stock · 20,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2016 Filed Sep 29, 2016 21:05 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,000 | $36.05 | $72,100.00 |
DisclosureSEC source: 0000874015-16-000138 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife Disclosed balance after: 2,170 F3 · kind: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/15. F3 · shares: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/15. Read SEC document |
| September 27, 2016 Filed Sep 29, 2016 21:05 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,000 | $10.29 | $20,580.00 |
DisclosureSEC source: 0000874015-16-000138 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife Disclosed balance after: 4,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/15. F3 · shares: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/15. Read SEC document |
| September 27, 2016 Filed Sep 29, 2016 21:05 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 20,000 | $36.02 | $720,400.00 |
DisclosureSEC source: 0000874015-16-000138 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,029 F1 · kind: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/15. F1 · shares: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/15. F2 · price: The sale was a result of shares owned. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.69 to $36.40, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 27, 2016 Filed Sep 29, 2016 21:05 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 20,000 | $10.29 | $205,800.00 |
DisclosureSEC source: 0000874015-16-000138 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/15. F1 · shares: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/15. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 22:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-16-000137 · edgar.xml · derivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 11,500 Underlying: Common Stock · 2,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 22:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-16-000137 · edgar.xml · derivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,259 Underlying: Common Stock · 20,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 22:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,000 | $35.50 | $71,000.00 |
DisclosureSEC source: 0000874015-16-000137 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,170 F3 · kind: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/15. F3 · shares: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/15. F4 · price: The sale was a result of shares owned. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.44 to $35.61, inclusive. The reporting person's wife undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 22:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,000 | $10.29 | $20,580.00 |
DisclosureSEC source: 0000874015-16-000137 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 4,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/15. F3 · shares: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/15. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 22:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 20,000 | $35.50 | $710,000.00 |
DisclosureSEC source: 0000874015-16-000137 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,029 F1 · kind: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/15. F1 · shares: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/15. F2 · price: The sale was a result of shares owned. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.44 to $35.61, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 22:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 20,000 | $10.29 | $205,800.00 |
DisclosureSEC source: 0000874015-16-000137 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/15. F1 · shares: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/15. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.